Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-19T04:12:57.527Z Has data issue: false hasContentIssue false
  • English
  • Français

Escitalopram in Obsessive-Compulsive Disorder: Response of Symptom Dimensions to Pharmacotherapy

Published online by Cambridge University Press:  07 November 2014

Dan J. Stein ,
Paul D. Carey ,
Christine Lochner ,
Soraya Seedat ,
Naomi Fineberg  and
Elisabeth Wreford Andersen
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction:

There is a substantial body of evidence that obsessive-compulsive disorder (OCD) symptoms can be grouped into a series of discrete dimensions, and some evidence that not all OCD symptom dimensions respond equally well to pharmacologic or psychotherapeutic intervention. The response of OCD symptom dimensions to 12 weeks of treatment with escitalopram or placebo was investigated.

Methods:

Data from a randomized, double-blind, placebo-controlled study of escitalopram in 466 adults with OCD were analyzed. Exploratory factor analysis of individual items of the Yale-Brown Obsessive-Compulsive Scale checklist was performed and subscale scores based on the extracted factors were determined. Analyses of covariance were undertaken to determine whether inclusion of each subscale score in these models impacted on the efficacy of escitalopram versus placebo.

Results:

Exploratory factor analysis of individual Yale-Brown Obsessive-Compulsive Scale items yielded 5 factors (contamination/cleaning, harm/checking, hoarding/symmetry, religious/sexual, and somatic/hypochondriacal). Analyses of covariance including all the subscales demonstrated that escitalopram was more effective than placebo. There was a significant interaction for the hoarding/symmetry factor, which was associated with a poor treatment response.

Conclusion:

Escitalopram shows good efficacy across the range of OCD symptom dimensions. Nevertheless, hoarding/symmetry was associated with a poorer treatment response. Hoarding/symmetry may be particularly characteristic of an early-onset group of OCD patients, with the involvement of neurotransmitters other than serotonin. Further work is needed to delineate fully the subtypes of OCD, and their correlates with underlying psychobiology and treatment responsivity.

Type
Original Research
Information
CNS Spectrums , Volume 13 , Issue 6 , June 2008 , pp. 492 - 498
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Karno, M, Golding, JM, Sorenson, SB, Burnam, MA. The epidemiology of obsessivecompulsive disorder in five US communities. Arch Gen Psychiatry. 1988;45:1094–1099.CrossRefGoogle ScholarPubMed
2.Horwath, E, Weissman, MM. The epidemiology and cross-national presentation of obsessive-compulsive disorder. Psychiatric Clin N Am. 2000;23:493–507.CrossRefGoogle ScholarPubMed
3.Murray, CJL, Lopez, AD, eds. The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass: Harvard University Press (Global Burden of Disease and Injury Series, Vol. 1); 1996.Google Scholar
4.Stein, DJ, Allen, A, Bobes, J, et al.Quality of life in obsessive-compulsive disorder. CNS Spectr. 2000;5(suppl 4):37–39.CrossRefGoogle Scholar
5.DuPont, RL, Rice, DP, Shiraki, S, Rowland, CR. Economic costs of obsessive-compulsive disorder. Med Interface. 1995;8:102–109.Google ScholarPubMed
6.Hollander, E, Stein, DJ, Broatch, J, Himelein, C, Rowland, C. A pharmacoeconomic and quality of life study of obsessive-compulsive disorder. CNS Spectr. 1997;2:16–25.CrossRefGoogle Scholar
7.Ozaki, N, Goldman, D, Kaye, WH, et al.Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry. 2003;8:933–936.CrossRefGoogle ScholarPubMed
8.Adams, KH, Hansen, ES, Pinborg, LH, et al.Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol. 2005;8:391–401.CrossRefGoogle ScholarPubMed
9.Thorén, P, Asberg, M, Bertilsson, L, Mellström, B, Sjöqvist, F, Träskman, L. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry. 1980;37:1289–1294.CrossRefGoogle ScholarPubMed
10.Zohar, J, Insel, TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry. 1987;22:667–687.CrossRefGoogle ScholarPubMed
11.Joel, D, Doljansky, J, Roz, N, Rehavi, M. Role of the orbital cortex and of the serotonergic system in a rat model of obsessive compulsive disorder. Neuroscience. 2005;130:25–36.CrossRefGoogle Scholar
12.Eddy, KT, Dutra, L, Bradley, R, Westen, D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004;24:1011–1030.CrossRefGoogle ScholarPubMed
13.Stein, DJ. Obsessive-compulsive disorder. Lancet. 2002;360:397–405.CrossRefGoogle ScholarPubMed
14.Stein, DJ, Fineberg, N, Seedat, S. An integrated approach to the treatment of OCD. In: Fineberg, N, Marazziti, D, Stein, DJ, eds. Obsessive-Compulsive Disorder: A Practical Guide. London, England: Martin Dunitz; 2001:167–176.Google Scholar
15.Lochner, C, Stein, DJ. Heterogeneity of obsessive-compulsive disorder: a literature review. Harv Rev Psychiatry. 2003;11:113–132.CrossRefGoogle ScholarPubMed
16.Rauch, SL, Dougherty, D, Shin, LM, et al.Neural correlates of factor-analyzed OCD symptom dimensions: a PET study. CNS Spectr. 1998;3:37–43.CrossRefGoogle Scholar
17.Cavallini, MC, Di Bella, D, Siliprandi, F, Malchiodi, F, Bellodi, L. Exploratory factor analysis of obsessive-compulsive patients and association with 5-HTTLPR polymorphism. Am J Med Genet. 2002;114:347–353.CrossRefGoogle ScholarPubMed
18.Lochner, C, Kinnear, CJ, Hemmings, SM, et al.Hoarding in obsessive-compulsive disorder: clinical and genetic correlates. J Clin Psychiatry. 2005;66:1155–1160.CrossRefGoogle ScholarPubMed
19.Rachman, S, Hodgson, RJ. Obsessions and Compulsions. Englewood-Cliffs, NJ: Prentice-Hall; 1980.Google Scholar
20.Buchanan, AW, Meng, KS, Marks, IM. What predicts improvement and compliance during the behavioral treatment of obsessive compulsive disorder? Anxiety. 1996;2:22–27.3.0.CO;2-F>CrossRefGoogle ScholarPubMed
21.Alarcon, RD, Libb, JW, Spitler, D. A predictive study of obsessive-compulsive disorder response to clomipramine. J Clin Psychopharmacol. 1993;13:210–213.CrossRefGoogle ScholarPubMed
22.Ravizza, L, Barzega, G, Bellino, S, Bogetto, F, Maina, G. Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry. 1995;56:368–373.Google ScholarPubMed
23.Black, DW, Monahan, P, Gable, J, Blum, N, Clancy, G, Baker, P. Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. J Clin Psychiatry. 1998;59:420–425.CrossRefGoogle ScholarPubMed
24.Mataix-Cols, D, Rauch, SL, Manzo, PA, Jenike, MA, Baer, L. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 1999;156:1409–1416.CrossRefGoogle ScholarPubMed
25.Stein, DJ, Andersen, EW, Overo, KF. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. Rev Bras Psiquiatr. 2007;29:303–307.CrossRefGoogle ScholarPubMed
26.Sánchez, C, Bøgesø, KPEbert, B, Reines, EH, Braestrup, C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl). 2004;174:163–176.CrossRefGoogle ScholarPubMed
27.Llorca, PM, Azorin, JM, Despiegel, N, Verpillat, P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Practice. 2005;59:268–275.CrossRefGoogle ScholarPubMed
28.Bielski, RJ, Bose, A, Chang, CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry. 2005;17:65–69.CrossRefGoogle ScholarPubMed
29.Lader, M, Stender, K, Bürger, V, Nil, R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety. 2004;19:241–248.CrossRefGoogle ScholarPubMed
30.Diagnostic and Statistical Manual for Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Publishing; 2000.Google Scholar
31.Goodman, WK, Price, LH, Rasmussen, SA, et al.The Yale—Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006–1011.CrossRefGoogle ScholarPubMed
32.Sheehan, DV, Lecrubier, Y, Sheehan, KH, et al.The Mini-International Neuropsychiatrie Interview (M.I.N.l.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl) 20:22–33.Google Scholar
33.Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.CrossRefGoogle ScholarPubMed
34.Krzanowski, WJ. Principles of Multivariate Analysis: A User's Perspective. New York, NY: Oxford University Press; 2000.CrossRefGoogle Scholar
35.Mataix-Cols, D, Rosario-Campos, MC, Leckman, JF. A multidimensional model of obsessive-compulsive disorder. Am J Psychiatry. 2005;162:228–238.CrossRefGoogle ScholarPubMed
36.Alonso, P, Menchon, JM, Pifarre, J, et al.Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry. 2001;62:535–540.CrossRefGoogle ScholarPubMed
37.Stein, DJ, Montgomery, SA, Kasper, S, Tanghoj, P. Predictors of response to pharmacotherapy with Citalopram in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001;16:357–361.CrossRefGoogle ScholarPubMed
38.Erzegovesi, S, Cavallini, MC, Cavedini, P, Diaferia, G, Locatelli, M, Bellodi, L. Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol. 2001;21:488–492.CrossRefGoogle ScholarPubMed
39.Shetti, CN, Reddy, YC, Kandavel, T, et al.Clinical predictors of drug nonresponse in obsessive-compulsive disorder. J Clin Psychiatry. 2005;66:1517–1523.CrossRefGoogle ScholarPubMed
40.Denys, D, Burger, H, van Megen, H, de Geus, F, Westenberg, H. A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2003;18:315–322.Google ScholarPubMed
41.Hollander, E, Kaplan, A, Schmeidler, J, et al.Neurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 2005;17:472–477.CrossRefGoogle ScholarPubMed
42.Saxena, S, Maidment, KM, Vapnik, T, et al.Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment. J Clin Psychiatry. 2002;63:21–27.CrossRefGoogle ScholarPubMed
43.Winsberg, ME, Cassic, KS, Koran, LM. Hoarding in obsessive-compulsive disorder; a report of 20 cases. J Clin Psychiatry. 1999;60:591–597.CrossRefGoogle ScholarPubMed
44.Liang, KY, Wang, Y, Shugart, YYet al.Evidence for potential relationship between SLC1A1 and a putative genetic linkage region on chromosome 14q to obsessive-compulsive disorder with compulsive hoarding. Am J Med Genet B Neuropsychiatr Genet. 2008;Feb 19 [Epub ahead of print].Google Scholar
45.Saxena, S, Brody, AL, Maidment, KM, et al.Cerebral glucose metabolism in obsessive-compulsive hoarding. Am J Psychiatry. 2004;161:1038–1048.CrossRefGoogle ScholarPubMed
46.Mataix-Cols, D, Wooderson, S, Lawrence, N, Brammer, MJ, Speckens, A, Phillips, ML. Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessive-compulsive disorder. Arch Gen Psychiatry. 2004;61:564–576.CrossRefGoogle ScholarPubMed
47.Mataix-Cols, D, Baer, L, Rauch, SL, Jenike, MA. Relation of factor-analyzed symptom dimensions of obsessive-compulsive disorder to personality disorders. Acta Psychiatr Scand. 2000;102:199–202.CrossRefGoogle ScholarPubMed
48.Stein, DJ, Seedat, S, Potocnik, F. Hoarding: a review. Isr J Psychiatry Relat Sci. 1999;36:35–46.Google ScholarPubMed
49.Saxena, S, Brody, AL, Maidment, KM, et al.Paroxetine treatment of compulsive hoarding. J Psychiatric Pes. 2007;41:481–487.Google ScholarPubMed